

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Alexa Fluor(R) 488 anti-human CD3

RRID:AB_389310

Type: Antibody

Proper Citation

BioLegend Cat# 300415, RRID:AB_389310

Antibody Information

URL: http://antibodyregistry.org/AB_389310

Proper Citation: BioLegend Cat# 300415, RRID:AB_389310

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-F

Antibody Name: Alexa Fluor(R) 488 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_389310

Vendor: BioLegend

Catalog Number: 300415

Alternative Catalog Numbers: 300454

Record Creation Time: 20250820T042911+0000

Record Last Update: 20250820T190601+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 488 anti-human CD3.

No alerts have been found for Alexa Fluor(R) 488 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lin H, et al. (2025) Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses. *Cell reports. Medicine*, 6(5), 102117.

Hu X, et al. (2025) Hypoimmune CD19 CAR T cells evade allojection in patients with cancer and autoimmune disease. *Cell stem cell*, 32(9), 1356.

Kang N, et al. (2025) T cell monocyte complexes exhibit distinct immune signatures during infection. *iScience*, 28(9), 113432.

Chancellor A, et al. (2025) The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells. *Immunity*, 58(2), 431.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

Xu Y, et al. (2025) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. *Cell*.

Sponaule A, et al. (2023) Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV. *Cell reports. Medicine*, 4(11), 101268.

Bradford HF, et al. (2023) Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFN γ and B cell subsets. *Cell reports. Medicine*, 4(1), 100894.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Riding AM, et al. (2022) Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence. *iScience*, 25(7), 104660.

Tuong ZK, et al. (2021) Resolving the immune landscape of human prostate at a single-cell level in health and cancer. *Cell reports*, 37(12), 110132.

Joly-Battaglini A, et al. (2016) Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. *F1000Research*, 5, 38.